Evaluate the Safety and Clinical Activity of HH2853

Required: EZH2 mutation

other relapsed/refractory non-Hodgkin's lymphomas with EZH2 mutation, and advanced solid tumors with specific genetic alterations, including EZH2 mutation

Required: SMARCB1 deficiency

advanced solid tumors with specific genetic alterations, including ... INI1 deficiency

Required: BAP1 deficiency

advanced solid tumors with specific genetic alterations, including ... BAP1 deficiency

Required: ARID1A mutation

advanced solid tumors with specific genetic alterations, including ... ARID1A mutation

Required: SMARCA4 mutation

advanced solid tumors with specific genetic alterations, including ... SMARCA4 mutation

Must have received: systemic therapy (anti-CD20 monoclonal antibody)

at least two lines of systemic therapy (at least one regimen based on anti-CD20 monoclonal antibodies)

Must have received: systemic therapy (CD20 monoclonal antibody)

at least two treatment regimens in the past (at least one with CD20 monoclonal antibody as the main treatment, with a maximum number of treatment lines<5)

Must have received: systemic therapy

Relapsed/refractory clinicopathologically documented PTCL with at least 1 line of prior systemic treatment (maximum <5 lines)

Must have received: any standard therapy

Patients must experience at least one prior standard therapy. Disease progression occurred on or after last line of therapy, or intolerant to last line of therapy (maximum ≤3 lines, Patients without treatment options available known to provide clinical benefit are also eligible upon agreement from investigator and sponsor)

Must have received: any treatment

Patients with unresectable locally delayed or metastatic epithelioid sarcoma who have undergone treatment (including those who have failed treatment and developed intolerable toxicity)

Cannot have received: EZH2 or EZH1/2 inhibitor

Previously received treatment with EZH2 or EZH1/2 inhibitors

Cannot have received: transplant

Patients with prior transplant are excluded